ArticleMicrobiology spectrum2026
MPT64 antigen-induced immune responses as a novel diagnostic tool for tuberculosis.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate novel antigen targets from the region of difference (RD) in Bacillus Calmette-Guérin (BCG) for improving tuberculosis (TB) diagnosis. Seven RD region antigens of IMPORTANCE: MPT64 is a protein from the tuberculosis (TB) bacterium that triggered the strongest immune response among seven new antigens tested. It shows great promise for making TB diagnosis more accurate. MPT64 worked well in different test formats, including blood tests that measure a key immune molecule (interferon-gamma), tests that detect TB antibodies, and skin tests like the TB skin test. It also performed strongly when combined with another TB antigen fusion called CLE (a merger of two other TB proteins, early secretory antigenic target-6 [ESAT-6] and culture filtrate protein-10 [CFP-10]). These results suggest that adding MPT64 to current TB tests could help doctors detect TB infection more easily and reliably.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.